TNG462

Phase 2Small molecule

TTango Therapeutics, Inc.

TNG462 is one of 48 small molecule programs targeting MTAP-deleted Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MTAP-Deleted Solid TumorsActive, not recruiting

EfficacyRecruiting

MTAP-Deleted Solid TumorsPreclinical

Active, not recruiting

EfficacyPhase 2

Recruiting

Competition

Competitive Landscape

145 competitors in Efficacy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

5 2

Oncovin

Eli Lilly

Phase 3

4 3

Vabysmo

Roche

Phase 3

2 4

Adriamycin

Pfizer

Phase 3

2 5

Soliris

AstraZeneca

Phase 3

1 6

Paraplatin

AAvyxa

Phase 3

4 7

Alimta

SShawn Eagle

Phase 3

3 8

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 9

QL2107

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 10

Endothelin Receptor Antagonist

RRadboud University Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

MTAP-Deleted Solid Tumors

NCT06188702

Q4 2027

Phase 1/2Recruiting

Efficacy

NCT06922591

Q2 2028

PreclinicalRecruiting

Locally Advanced Solid Tumor

NCT05732831

Clinical

Trials by Indication[1]

Efficacy1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting·TTango Therapeutics, Inc.·Phase 1/2·NCT06922591·183 enrolled

Locally Advanced Solid Tumor1 trial

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Recruiting·TTango Therapeutics, Inc.·Preclinical·NCT05732831·225 enrolled

MTAP-deleted Solid Tumors1 trial

A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP

Active, not recruiting·SServier Bio-Innovation LLC·Preclinical·NCT06188702·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TNG462. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TNG462 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TNG462. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tango Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTango Therapeutics, Inc.

TNG462

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Efficacy1 trial

Locally Advanced Solid Tumor1 trial

MTAP-deleted Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News